# SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07535632/  
OnCo record `nct07535632` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sintilimab and bevacizumab (glioblastoma use) in colorectal cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.

## Summary

SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07535632 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 58 participants, started 2026-06-01 and due to reach its primary completion in 2028-06-01. Interventions recorded: SBRT; Sintilimab; Bevacizumab; Trifluridine and Tipiracil Tablets; Standard of Care (Investigator Selected). Conditions listed: Colorectal Neoplasms. Primary outcome: Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed colorectal cancer with unresectable metastatic or recurrent lesions". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: BEST
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07535632
- Phase: 2
- Setting: A Phase II Clinical Study on the Efficacy of Stereotactic Body Radiation Therapy Sequential Combined With Bevacizumab and Trifluridine/Tipiracil in the Treatment of Recurrent Metastatic Colorectal Cancer(BEST)
- Sponsor: Shanghai Zhongshan Hospital
- Enrolled: 58

## Sources

- ClinicalTrials.gov NCT07535632: https://clinicaltrials.gov/study/NCT07535632

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07535632.json